Melinta Therapeutics Inc. will sell its first commercial drug – the antibiotic Baxdela (delafloxacin) – independently through a hospital-based commercial organization that is in the process of being built, according to CEO Eugene Sun.
FDA approved the fluoroquinolone antibiotic June 19 for the treatment of acute bacterial skin and skin structure infections (ABSSI) in...






